Promising Diabetes Therapy Based on the Molecular Mechanism for Glucose Toxicity: Usefulness of SGLT2 Inhibitors as well as Incretin-Related Drugs

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|27|3044-3051

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.27, 2016-09, pp. : 3044-3051

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SGLT2 inhibitors look promising for glycaemic control

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 16-17

Adis International

Access to resources Recommend Favorite

Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo  

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

By Scheen André J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 647-663

Informa Healthcare

Access to resources Recommend Favorite

Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 17, Iss. 4, 2017-11 ,pp. : 297-302

Bentham Science Publishers

Access to resources Recommend Favorite

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents

By Washburn William N  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 5, 2012-05 ,pp. : 483-494

Informa Healthcare

Access to resources Recommend Favorite